Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COUNTERFEIT OVULEN-21 RESURFACES IN FOXMEYER WAREHOUSE, CUSTOMER PHARMACIES, HHS

Executive Summary

COUNTERFEIT OVULEN-21 RESURFACES IN FOXMEYER WAREHOUSE, CUSTOMER PHARMACIES, HHS announced in a Sept. 27 press release. According to the release, FDA has advised consumers in Texas and Oklahoma that counterfeit Ovulen-21 contraceptive tablet refills bearing the lot number -489 have been found in distribution in the two states. "FoxMeyer officials say they do not know how ]the[ suspect product came into its possession. . .but 50 counterfeit Ovulen-21 refills with the -489 lot number have been located in FoxMeyer-supplied pharmacies in the two states and five cartons were found in a FoxMeyer warehouse," HHS reported. Searle recalled two lots of Ovulen-21 (441 and 489) last November after the company and FDA were alerted that counterfeit versions of the contraceptive were in trade channels ("The Pink Sheet" Nov. 5, 1984 T&G-3). Like the products first recalled by Searle, the second batch of counterfeits has been found to be subpotent. Searle told whslrs. in November that counterfeit Ovulen lot 441 was in distribution in 1984 by Interstate Drug Exchange of Plainview, New York, and from Interstate to other unauthorized whslrs. According to HHS, none of the two suspect lots were found in FoxMeyer's possession last fall.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel